LAB Research adds CRO veteran Daniel Menard to its management team as
Canadian and Hungarian sites's activity climb to historical highs.
LAVAL, QC,
"We are thrilled to welcome Dr. Ménard to LAB Research
Dr. Ménard was until recently President and CEO of Algos Therapeutics Inc. where he spearheaded the transition of Algos' business model of proprietary drug development to a mature CRO; Algos Preclinical Services. Previously to Algos, Dr. Ménard was Vice-President, General Manager, Pharmacology & Metabolism resources at MDS Pharma Services where he managed a global organization of more than 250 people based in
About LAB Research Inc.:
LAB Research is a Canadian global non-clinical contract research organization that provides contract research services to the pharmaceutical, biotechnology, agro-chemical, petro-chemical and industrial markets. LAB Research supports the development of its customers' products from three state-of-the-art facilities located in
LAB Research's shares trade on the TSX under the symbol "LRI", with 18.1 million shares outstanding.
This news release contains certain forward-looking statements that reflect the current views and/or expectations of LAB Research Inc. with respect to its performance, business and future events. Such statements are subject to a number of risks, uncertainties and assumptions. Actual results and events may vary significantly.
%SEDAR: 00023798EF
For further information: For further information: visit LAB Research's website at www.labresearch.com, or contact: Luc Mainville, Chief Executive Officer,: (450) 973-2240 (ext. 1206), [email protected]; Frédéric Dumais, Partner, Jasmin-Dumais Financial Communications, (514) 862-1251, [email protected]
Share this article